MannKind (NASDAQ:MNKD) Posts Earnings Results

MannKind (NASDAQ:MNKD) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.05, FiscalAI reports. The business had revenue of $101.87 million for the quarter, compared to analysts’ expectations of $107.74 million. The company’s revenue for the quarter was up 24.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.03 EPS.

Here are the key takeaways from MannKind’s conference call:

• Revenue growth broadened beyond collaborations: Third-quarter revenue rose 24% to $101.9 million, with commercial product revenue roughly doubling to $45 million. Tyvaso DPI royalties increased 12% to $37.5 million, while MannKind said its United Therapeutics agreement is expected to provide more than $1 billion in revenue from 2027 through 2030.
• FUROSCIX ReadyFlow adoption is moving quickly: About 75% of shipments had shifted to ReadyFlow by late October, and the company expects fourth-quarter FUROSCIX sales to roughly match first-half 2026 sales. ReadyFlow’s lower cost of goods could also improve margins as the transition progresses.
• Afrezza’s pediatric launch is gaining traction, but the adult business has underperformed: Pediatric patients now account for about one in four prescriptions, and new-to-brand prescriptions rose nearly 80% sequentially. Management attributed adult weakness partly to reduced promotional support and field-team turnover, and said it plans to refocus resources.
• Management expects a return to profitability: Despite a third-quarter GAAP net loss of $23.2 million, the company expects GAAP and non-GAAP profitability in the fourth quarter and annual profitability in 2027, while continuing to invest in commercial growth.
• Nintedanib DPI advanced, with a longer-term clinical milestone ahead: MannKind reported positive Phase I-B safety and tolerability results and is starting its streamlined Phase II study, with a readout expected in the first half of 2028. The timeline could move faster if the FDA supports adding U.S. sites.

MannKind Stock Performance

MNKD traded up $0.14 on Friday, reaching $3.90. 4,984,958 shares of the company’s stock were exchanged, compared to its average volume of 3,481,324. MannKind has a twelve month low of $2.23 and a twelve month high of $6.51. The company’s 50 day moving average is $3.55 and its 200-day moving average is $3.71. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -16.96 and a beta of 1.10.

Insiders Place Their Bets

In other news, Director Steven Binder sold 39,051 shares of the stock in a transaction on Friday, September 25th. The shares were sold at an average price of $3.29, for a total value of $128,477.79. Following the completion of the sale, the director owned 713,258 shares of the company’s stock, valued at $2,346,618.82. This represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have commented on MNKD shares. Truist Financial lowered their price target on MannKind from $6.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. HC Wainwright reiterated a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Wall Street Zen raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital initiated coverage on shares of MannKind in a report on Monday, October 19th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Wells Fargo & Company dropped their price target on shares of MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.33.

Trending Headlines about MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Analysts raised price targets. Cantor Fitzgerald lifted its target to $10 from $8 and maintained an “overweight” rating. RBC raised its target to $5 from $4.75, while keeping a “sector perform” rating. Cantor Fitzgerald analyst information RBC price target report
• Positive Sentiment: Longer-term revenue and profitability outlook. MannKind expects its United Therapeutics agreement to generate about $1 billion in revenue from 2027 through 2030, and is targeting profitability in the fourth quarter. United Therapeutics deal and profitability outlook
• Neutral Sentiment: Quarterly results were mixed. MannKind’s revenue rose 24% year over year to $101.87 million, and its reported loss per share was narrower than the consensus estimate. MannKind third-quarter results
• Negative Sentiment: Revenue missed expectations, and the company remained loss-making. Sales of $101.87 million were below analysts’ $107.74 million estimate, while EPS was down from a profit in the year-ago quarter. Q3 loss and revenue miss

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).